Effect and safety of tamsulosin, the prostate specific alpha(1)-blocker, in the treatment of BPH (benign prostatic hyperplasia)

被引：2
|
作者：
Kawabe, K
机构：
[1] Department of Urology, Faculty of Medicine, The University of Tokyo, Tokyo
来源：
AKTUELLE UROLOGIE | 1996年 / 27卷
关键词：
BPH; alpha-blocker; alpha(1a)-receptor-subtype; tamsulosin;
D O I：
10.1055/s-2008-1055642
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Clinical trials of tamsulosin demonstrate that it is an effective treatment modality for the symptoms associated with BPH, and it has practically no effect on blood pressure at a dose of 0.2 mg. This is probably due to its selective affinity for the prostate, which may be due to the strong affinity of tamsulosin for the alpha(1a)-receptor subtype.
引用
收藏
页码：25 / 26
页数：2
相关论文
共 50 条
  • [31] Effect of Selective Alpha-blocker Tamsulosin on Erectile Function in Patients With Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
    Shelbaia, Ahmed
    Elsaied, Wael M.
    Elghamrawy, Hisham
    Abdullah, Ahmed
    Salaheldin, Mohamed
    UROLOGY, 2013, 82 (01) : 130 - 135
  • [32] A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha(1A)-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia)
    Abrams, P
    Speakman, M
    Stott, M
    Arkell, D
    Pocock, R
    BRITISH JOURNAL OF UROLOGY, 1997, 80 (04): : 587 - 596
  • [33] The effect of tamsulosin and dutasteride combination drug therapy on prostate volume in patients with benign prostatic hyperplasia
    Nandana, P., I
    Adipura, L. R.
    Rasyid, H.
    3RD INTERNATIONAL CONFERENCE ON BIOSCIENCE AND BIOTECHNOLOGY, 2021, 712
  • [34] Comparison of a phytotherapeutic agent (Permixon) with an α-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia:: A 1-year randomized international study
    Debruyne, F
    Koch, G
    Boyle, P
    Da Silva, FC
    Gillenwater, JG
    Hamdy, FC
    Perrin, P
    Teillac, P
    Vela-Navarrete, R
    Raynaud, JP
    EUROPEAN UROLOGY, 2002, 41 (05) : 497 - 506
  • [35] The selective α-blocker alfuzosin in the treatment of benign prostatic hyperplasia
    Mazo, EB
    Matushevsky, IA
    Nikitin, YY
    TERAPEVTICHESKII ARKHIV, 1997, 69 (10) : 79 - 82
  • [36] The Change of Testosterone Secretion During the Treatment of Alpha-1 Blocker in Patients with Benign Prostatic Hyperplasia
    Matsukawa, Yoshihisa
    Takai, Shun
    Funahashi, Yasuhito
    Kato, Masashi
    Yamamoto, Tokunori
    Hirakawa, Akihiro
    Gotoh, Momokazu
    UROLOGY, 2016, 88 : 149 - 154
  • [37] Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial
    Gotoh, M
    Kamihira, O
    Kinukawa, T
    Ono, Y
    Ohshima, S
    Origasa, H
    BJU INTERNATIONAL, 2005, 96 (04) : 581 - 586
  • [38] A Review of Laser Treatment for Symptomatic BPH (Benign Prostatic Hyperplasia)
    Shiva Madhwan Nair
    Marie Adrianne Pimentel
    Peter John Gilling
    Current Urology Reports, 2016, 17
  • [39] Current role of lasers in the treatment of benign prostatic hyperplasia (BPH)
    Kuntz, Rainer M.
    EUROPEAN UROLOGY, 2006, 49 (06) : 961 - 969
  • [40] Phytopharmaceutical and synthetic agents in the treatment of benign prostatic hyperplasia (BPH)
    Bach, D
    Schmitt, M
    Ebeling, L
    PHYTOMEDICINE, 1997, 3 (04) : 309 - 313
12345